ライフサイエンスコーパス: peripartum

1 Peripartum administration of single-dose nevirapine redu

2 geometric mean concentrations between their peripartum and follow-up levels for immunoglobulin G to

3 There is a paucity of data on peripartum and long-term clinical outcomes in women with

4 ose vaccination (to 80% of neonates), use of peripartum antivirals (to 80% of hepatitis B e antigen-p

5 Although the frequency of peripartum cardiomyopathy (185 of 100,000 deliveries) at

6 e: idiopathic cardiomyopathy (616 patients), peripartum cardiomyopathy (51); and cardiomyopathy due t

7 5), hypertrophic cardiomyopathy (n = 40) and peripartum cardiomyopathy (n = 69) for disease-causing P

8 Peripartum cardiomyopathy (PPCM) and dilated cardiomyopa

9 t ventricular (LV) recovery in patients with peripartum cardiomyopathy (PPCM) and to record rates of

10 The term peripartum cardiomyopathy (PPCM) describes dilated cardi

11 Peripartum cardiomyopathy (PPCM) disproportionately affe

12 Peripartum cardiomyopathy (PPCM) is a life-threatening p

13 Peripartum cardiomyopathy (PPCM) is a pregnancy-associat

14 Peripartum cardiomyopathy (PPCM) is a rare life-threaten

15 Peripartum cardiomyopathy (PPCM) is an often fatal disea

16 Peripartum cardiomyopathy (PPCM) is the unexplained loss

17 this study was to systematically review the peripartum cardiomyopathy (PPCM) literature and determin

18 Peripartum cardiomyopathy (PPCM) remains a major cause o

19 psia is a risk factor for the development of peripartum cardiomyopathy (PPCM), but it is unknown whet

20 Black women are at greater risk for peripartum cardiomyopathy (PPCM).

21 imbalance during pregnancy may lead to acute peripartum cardiomyopathy (PPCM).

22 describe the characteristics and outcomes of peripartum cardiomyopathy (PPCMP) patients who received

23 verexpression of Galpha(q) exhibit a lethal, peripartum cardiomyopathy accompanied by apoptosis.

24 A comparison between the peripartum cardiomyopathy and early pregnancy-associated

25 rdiology, we identified 44 women who had had peripartum cardiomyopathy and had a total of 60 subseque

26 She was diagnosed with peripartum cardiomyopathy and treatment with digoxin and

27 Patients with peripartum cardiomyopathy appear to have a better progno

28 idiopathic cardiomyopathy, the patients with peripartum cardiomyopathy had better survival (adjusted

29 For decades, peripartum cardiomyopathy has remained an enigma.

30 Peripartum cardiomyopathy has variable disease progressi

31 Mortality rates in peripartum cardiomyopathy have decreased, and this is mo

32 mation has also indicated that many cases of peripartum cardiomyopathy have genetic underpinnings.

33 Conversely, sNix protected against apoptotic peripartum cardiomyopathy in G(alpha)q-overexpressors.

34 view are to describe the clinical profile of peripartum cardiomyopathy in the United States and to pr

35 Peripartum cardiomyopathy is a cardiomyopathy of unknown

36 Peripartum cardiomyopathy is a heart disease of unknown

37 Peripartum cardiomyopathy is a potentially life-threaten

38 Peripartum cardiomyopathy is a pregnancy-associated myoc

39 Peripartum cardiomyopathy is a rare and sometimes fatal

40 Peripartum cardiomyopathy is a rare complication of preg

41 Peripartum cardiomyopathy is a rare lethal disease about

42 sequent pregnancy in women with a history of peripartum cardiomyopathy is associated with a significa

43 search in the past decade has suggested that peripartum cardiomyopathy is caused by vascular dysfunct

44 Management of peripartum cardiomyopathy is largely limited to the same

45 hy and myocarditis, but its effectiveness in peripartum cardiomyopathy is unknown.

46 cular function and survival in the Galpha(q) peripartum cardiomyopathy model.

47 Based on clinical observations of peripartum cardiomyopathy patients and the high rate of

48 Peripartum cardiomyopathy patients had a high incidence

49 Peripartum cardiomyopathy patients had a mean age of 31+

50 For >50% of peripartum cardiomyopathy patients, left ventricular fun

51 Peripartum cardiomyopathy seems to affect women in diffe

52 omen had a 15.7-fold higher relative risk of peripartum cardiomyopathy than non-African Americans (od

53 men have significantly higher odds of having peripartum cardiomyopathy that could not be explained by

54 tutes of Health (NIH) convened a Workshop on Peripartum Cardiomyopathy to foster a systematic review

55 ared the clinical outcomes of six women with peripartum cardiomyopathy treated with intravenous immun

56 The frequency of peripartum cardiomyopathy varies markedly between Africa

57 U.S. studies confirmed that the frequency of peripartum cardiomyopathy was significantly higher among

58 icity remained a significant risk factor for peripartum cardiomyopathy when other risk factors were c

59 Given the poor prognosis of women with peripartum cardiomyopathy who do not improve, this thera

60 thy was a prospective 30-center study of 100 peripartum cardiomyopathy women with LV ejection fractio

61 gy, clinical presentation, and management of peripartum cardiomyopathy, as well as the current knowle

62 shed from 1966 to July 1999, using the terms peripartum cardiomyopathy, cardiomyopathy, and pregnancy

63 this small retrospective study of women with peripartum cardiomyopathy, patients treated with immune

64 entricular function in women presenting with peripartum cardiomyopathy.

65 erican women are at increased risk of having peripartum cardiomyopathy.

66 imilar to those of patients with traditional peripartum cardiomyopathy.

67 ne hundred women met traditional criteria of peripartum cardiomyopathy; 23 were diagnosed with pregna

68 Women with detectable peripartum CMV viruria were more likely to have infants

69 Despite the lack of catastrophic peripartum complications, the prevalence of both aortic

70 ned formula-fed infants born to women with a peripartum diagnosis of HIV type 1 (HIV-1) infection to

71 isorders of pregnancy, gestational diabetes, peripartum dissection, polycystic ovarian syndrome, etc.

72 eviously been randomly assigned to a single, peripartum dose of nevirapine or placebo in a trial in B

73 d within 6 months after receipt of a single, peripartum dose of nevirapine.

74 disorder in women that might be triggered by peripartum fluctuations in reproductive hormones.

75 hlorodiphenyldichloroethylene), and maternal peripartum hair mercury (Hg) levels were measured to est

76 enta accreta is one of the leading causes of peripartum hemorrhage.

77 and to examine a modern approach to massive peripartum hemorrhage.

78 viruses were associated with reduced risk of peripartum HIV infection in the historic U.S. Woman and

79 stered soon after birth, before in utero and peripartum HIV infection is excluded.

80 cific IgG antibodies associated with reduced peripartum HIV transmission risk in this cohort.

81 ve strategies for preventing and controlling peripartum infection should be an obstetrical priority.

82 ing cause of neonatal sepsis and meningitis, peripartum infections in women, and invasive infections

83 Median peripartum maternal log2 sCD14 concentration was higher

84 ative polymerase chain reaction) measured in peripartum maternal plasma; 161 (33%) were anti-HCV-posi

85 g, and largely prevented lethality in the Gq peripartum model of apoptotic cardiomyopathy.

86 Despite significant progress in reducing peripartum mother-to-child transmission (MTCT) of human

87 Despite significant progress in reducing peripartum MTCT of HIV with ART, continued access to ART

88 Peripartum or postpartum SHIV infection (n = 3) resulted

89 ociated disease that typically arises in the peripartum period and is marked by left ventricular dysf

90 myopathy of unknown cause that occurs in the peripartum period in previously healthy women.

91 eriment, we administered estrogen during the peripartum period to determine if estrogen supplementati

92 re than 5 months after delivery (outside the peripartum period) up to 34 years 7 months.

93 rom uninfected dams, particularly during the peripartum period, suggesting that close contact during

94 third of CMV infections occurred during the peripartum period, with 40% acquired through breastfeedi

95 increased risk of cardiomyopathy during the peripartum period.

96 and quantitative HBsAg were measured in the peripartum period.

97 by excess anti-angiogenic signalling in the peripartum period.

98 nd the impact of medications used during the peripartum period.

99 the risk of cardiac events during different peripartum periods.

100 ose colonized with GBS and administration of peripartum prophylaxis to those identified as carriers t

101 ole in recognizing the signs and symptoms of peripartum psychiatric disorders, particularly postpartu

102 regnancy and the postpartum period to reduce peripartum relapse risk.

103 In women with prior exposure to peripartum single-dose nevirapine (but not in those with

104 x 2 factorial randomized clinical trial with peripartum (single-dose nevirapine vs placebo) and postp

105 ng, migraine, acute or chronic hypertension, peripartum state, or use of serotonergic drugs with clin

106 1%), with in utero transmission in 21 (36%), peripartum transmission in 26 (45%), and transmission vi

107 V-1 strains also predicted a reduced risk of peripartum transmission in secondary analyses.

108 Although neonatal sepsis due to the peripartum transmission of S. pneumoniae is rare, this c

109 ct with its central role in heterosexual and peripartum transmission, has important implications for

110 Peripartum variations in MIS type II receptor expression

111 Signs of severe sepsis in peripartum women, particularly with confirmed or suspect

112 l II, and Mortality Probability Model III in peripartum women.

113 e guidelines are applied in the treatment of peripartum women.